vimarsana.com
Home
Live Updates
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis : comparemela.com
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
Designation is based on results from the progressive pulmonary fibrosis cohort of the Phase 2 study assessing the safety and efficacy of BMS-986278 treatment versus placebo
...
Related Keywords
Bristol Myers Squibb ,
Roland Chen ,
Facebook ,
International Congress ,
Exchange Commission ,
Drug Administration ,
Linkedin ,
European Respiratory Society ,
Instagram ,
Neuroscience Development ,
Twitter ,
Youtube ,
Breakthrough Therapy Designation ,
Therapy Designation ,
Bristol Myers ,
Myers Squibb ,
Pioneering Paths Forward ,
Transform Patient ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
Markets ,
comparemela.com © 2020. All Rights Reserved.